Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04917796 · ClinicalTrials.gov registry record · NA

The Effect of Electroacupuncture on Nerve Pain Caused by Chemotherapy (Chemotherapy-Induced Peripheral Neuropathy)

A NA study of Pain and Chemotherapy-induced Peripheral Neuropathy, sponsored by Dana-Farber Cancer Institute.

Active
Registry status
NA
Development phase
255
Enrollment target
6
Study locations

NCT04917796: Active NA study of Pain and Chemotherapy-induced Peripheral Neuropathy, sponsored by Dana-Farber Cancer Institute.

NCT04917796 is a NA study of Pain and Chemotherapy-induced Peripheral Neuropathy that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 255 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (16% lower). The trial reports 6 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04917796, a NA study of Pain and Chemotherapy-induced Peripheral Neuropathy, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
255 participants
Enrollment target
6
Study locations

Study Summary

This study is a randomized controlled trial of electroacupuncture (referred to as EA) versus sham acupuncture (referred to as EA) as effective treatments for Chemotherapy-Induced Peripheral Neuropathy (CIPN) pain in cancer survivors.

Primary Outcome

The primary outcome will be the patient's rating of his/her average pain in the past 24 hours. All participants will fill out the Brief Pain Inventory-Short Form (BPI-SF)

Interventions

  • OTHER Electroacupuncture
  • OTHER Sham Acupuncture

Study Locations (6)

New Jersey

  • Memorial Sloan Kettering Basking Ridge (Limited protocol activities) - Basking Ridge
  • Memorial Sloan Kettering Monmouth (Limited protocol activities) - Middletown
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale

New York

  • Memorial Sloan - Kettering Cancer Center - New York
  • Memorial Sloan Kettering Nassau (Limited protocol activities) - Rockville Centre

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 255 participants
Start Date 2021-05-21
Est. Completion 2026-04-24
Phase NA
Dana-Farber Cancer Institute

781 total trials

What the registry record for NCT04917796 still lists

NCT04917796 is an interventional study that assigns participants to a tested intervention. The registered 255 participants enrollment target is mid-sized for trials with a published cap, below the 304-participant average among 374 other Pain trials with a reported enrollment target (16% lower).

The record links to 6 conditions, with Pain appearing as the primary indexed condition, and to 2 interventions - of which Electroacupuncture is the first listed.

NCT04917796 lists 6 locations in 3 states (New Jersey, New York, Massachusetts).

Frequently Asked Questions

What is clinical trial NCT04917796 about?

NCT04917796 is a clinical study titled "The Effect of Electroacupuncture on Nerve Pain Caused by Chemotherapy (Chemotherapy-Induced Peripheral Neuropathy)". This study is a randomized controlled trial of electroacupuncture (referred to as EA) versus sham acupuncture (referred to as EA) as effective treatments for Chemotherapy-Induced Peripheral Neuropathy (CIPN) pain in cancer survivors.

What is the current status of trial NCT04917796?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 255 participants. The study started on 2021-05-21. Estimated completion is 2026-04-24.

What conditions does trial NCT04917796 study?

This clinical trial studies the following conditions: Pain, Chemotherapy-induced Peripheral Neuropathy, Neuropathy, CIPN - Chemotherapy-Induced Peripheral Neuropathy, Nerve Pain.

What interventions are being tested in trial NCT04917796?

The interventions under investigation include: Electroacupuncture (OTHER), Sham Acupuncture (OTHER).

Who is sponsoring clinical trial NCT04917796?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04917796 being conducted?

This trial has 6 study locations across Massachusetts, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04917796's enrollment target sits among peer trials

255 69th of 374 higher than 306 of 374 other Pain trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04623424 · 255 participants

    Intestinal Microbiota in Stem Cell Transplant Transplant Admission

  • NCT05114798 · 255 participants · NA

    Time-restricted Eating Versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers

  • NCT05336188 · 255 participants · Phase 2

    Neurocognitive Mechanisms Underlying Smartphone-Assisted Prevention of Relapse in Opioid Use Disorder

  • NCT05486637 · 255 participants · Early Phase 1

    Vocal Emotion Communication With Cochlear Implants

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04917796, the US trial registry maintained by the National Library of Medicine. NCT04917796 (mid enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.